147 related articles for article (PubMed ID: 34803091)
1. Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure.
Suma S; Yokoyama Y; Momose H; Makishima K; Kiyoki Y; Sakamoto T; Kusakabe M; Kato T; Kurita N; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
Intern Med; 2022 Jun; 61(11):1673-1679. PubMed ID: 34803091
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.
Kanda J; Horwitz ME; Long GD; Gasparetto C; Sullivan KM; Chute JP; Morris A; Hennig T; Li Z; Chao NJ; Rizzieri DA
Bone Marrow Transplant; 2012 May; 47(5):700-5. PubMed ID: 21804612
[TBL] [Abstract][Full Text] [Related]
3. Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation.
Sumi M; Shimizu I; Sato K; Ueki T; Akahane D; Ueno M; Ichikawa N; Nakao S; Kobayashi H
Int J Hematol; 2010 Dec; 92(5):744-50. PubMed ID: 21052879
[TBL] [Abstract][Full Text] [Related]
4. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
Sharma P; Pollyea DA; Smith CA; Purev E; Kamdar M; Haverkos B; Sherbenou D; Rabinovitch R; Hammes A; Gutman JA
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1671-1677. PubMed ID: 29684565
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
6. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
Chewning JH; Castro-Malaspina H; Jakubowski A; Kernan NA; Papadopoulos EB; Small TN; Heller G; Hsu KC; Perales MA; van den Brink MR; Young JW; Prockop SE; Collins NH; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1313-23. PubMed ID: 17950918
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.
Hoshino T; Takada S; Hatsumi N; Sakura T
Int J Hematol; 2019 Apr; 109(4):463-469. PubMed ID: 30734904
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.
Waki F; Masuoka K; Fukuda T; Kanda Y; Nakamae M; Yakushijin K; Togami K; Nishiwaki K; Ueda Y; Kawano F; Kasai M; Nagafuji K; Hagihara M; Hatanaka K; Taniwaki M; Maeda Y; Shirafuji N; Mori T; Utsunomiya A; Eto T; Nakagawa H; Murata M; Uchida T; Iida H; Yakushiji K; Yamashita T; Wake A; Takahashi S; Takaue Y; Taniguchi S
Biol Blood Marrow Transplant; 2011 Jun; 17(6):841-51. PubMed ID: 20849969
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with MECOM-associated syndrome.
Irie M; Niihori T; Nakano T; Suzuki T; Katayama S; Moriya K; Niizuma H; Suzuki N; Saito-Nanjo Y; Onuma M; Rikiishi T; Sato A; Hangai M; Hiwatari M; Ikeda J; Tanoshima R; Shiba N; Yuza Y; Yamamoto N; Hashii Y; Kato M; Takita J; Maeda M; Aoki Y; Imaizumi M; Sasahara Y
Int J Hematol; 2023 Apr; 117(4):598-606. PubMed ID: 36515795
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.
Onishi Y; Mori T; Kako S; Koh H; Uchida N; Kondo T; Kobayashi T; Yabe H; Miyamoto T; Kato K; Suzuki R; Nakao S; Yamazaki H;
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2137-2142. PubMed ID: 28844947
[TBL] [Abstract][Full Text] [Related]
12. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
Choe HK; Gergis U; Mayer SA; Nagar H; Phillips AA; Shore TB; Smith MJ; van Besien K
Transplantation; 2017 Jan; 101(1):e34-e38. PubMed ID: 27764032
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
14. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
15. Salvage allogeneic hematopoietic SCT for primary graft failure in children.
Kato M; Matsumoto K; Suzuki R; Yabe H; Inoue M; Kigasawa H; Inagaki J; Koh K; Hashii Y; Tauchi H; Suminoe A; Kikuta A; Sakamaki H; Kawa K; Kato K; Fukuda T
Bone Marrow Transplant; 2013 Sep; 48(9):1173-8. PubMed ID: 23524639
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
17. Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.
Yoshihara S; Ikegame K; Taniguchi K; Kaida K; Kim EH; Nakata J; Kato R; Inoue T; Fujioka T; Tamaki H; Okada M; Soma T; Ogawa H
Bone Marrow Transplant; 2012 Mar; 47(3):369-73. PubMed ID: 21478920
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia.
Ghanem KM; Kharfan-Dabaja MA; El-Solh H; Harris N; Kreidieh N; Nehme R; Muwakkit SA; Saab R; Bazarbachi A; Abboud MR
Curr Res Transl Med; 2017 Sep; 65(3):115-119. PubMed ID: 28988743
[TBL] [Abstract][Full Text] [Related]
19. Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders.
Gupta A; Downey M; Shanley R; Jennissen C; Miller WP; Lund TC; Orchard PJ; Smith AR
Biol Blood Marrow Transplant; 2020 Mar; 26(3):486-492. PubMed ID: 31751770
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
